HLN (Haleon) Stock Based Compensation: $116 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HLN Haleon PLC HLN
70 GF Score
Price $9.71
GF Value $9.77
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Haleon Stock Based Compensation?

Haleon HLN -1.42% 70 Stock Based Compensation is $116 Mil as of Dec. 2025. GuruFocus rates HLN with a GF Score™ of 70/100 and a GF Value™ of $9.77 (Fairly Valued). The stock has 3 warning signs investors should review.

Haleon's Stock Based Compensation for the six months ended in Dec. 2025 was $59 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $116 Mil.

Haleon Stock Based Compensation Related Terms

Haleon Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Haleon's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleon Stock Based Compensation Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 18.27 96.20 128.95 115.13

Haleon Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 62.34 67.00 56.99 58.90
HLN
70GF Score
Haleon PLC HLN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleon Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $116 Mil.

What does a Stock Based Compensation of $116 Mil mean?
Haleon (HLN) has a Stock Based Compensation of $116 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Haleon and its competitors.
Is Haleon's Stock Based Compensation too high?
Haleon's current Stock Based Compensation is $116 Mil. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's Stock Based Compensation compare to ZTS and UTHR?
Haleon's Stock Based Compensation of $116 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Haleon and its competitors. Haleon's current Stock Based Compensation is $116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $9.77, compared to a current price of $9.71 — trading 0.6% below its estimated fair value. The current Stock Based Compensation is $116 Mil. Haleon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Haleon (HLN), the current Stock Based Compensation is $116 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleon (HLN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be undervalued. The current stock price of $9.71 is trading 0.6% below its estimated GF Value™ of $9.77. GuruFocus considers Haleon to be Fairly Valued.

Key valuation signals for HLN:

  • Stock Based Compensation: $116 Mil
  • GF Value™: $9.77 vs. price of $9.71 (0.6% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score

Get the complete analysis for HLN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.71
Price
$9.77
GF Value